Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLPT 
Clearpoint Neuro Inc (CLPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/07/2025: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29
1 Year Target Price $29
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.93% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 330.70M USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 2 | Beta 0.94 | 52 Weeks Range 5.49 - 19.22 | Updated Date 07/7/2025 |
52 Weeks Range 5.49 - 19.22 | Updated Date 07/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -64.51% | Operating Margin (TTM) -72.63% |
Management Effectiveness
Return on Assets (TTM) -32.39% | Return on Equity (TTM) -76.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 321751523 | Price to Sales(TTM) 10.26 |
Enterprise Value 321751523 | Price to Sales(TTM) 10.26 | ||
Enterprise Value to Revenue 9.98 | Enterprise Value to EBITDA -7.07 | Shares Outstanding 28265000 | Shares Floating 25400194 |
Shares Outstanding 28265000 | Shares Floating 25400194 | ||
Percent Insiders 8.25 | Percent Institutions 34.74 |
Upturn AI SWOT
Clearpoint Neuro Inc
Company Overview
History and Background
ClearPoint Neuro, Inc. was founded in 1998 as MRI Interventions, Inc. It initially focused on developing MRI-guided neurosurgical devices and has evolved into a company offering a platform for delivering drugs and gene therapies into the brain. The company's name changed to ClearPoint Neuro in 2019 to reflect its broader focus.
Core Business Areas
- Therapeutic Delivery: ClearPoint's flagship product is its neuro-navigation system used for delivering drugs, gene therapies, and other biologics directly into the brain. This includes the SmartFrame system and related navigation software.
- Neuro Navigation: Development and marketing of systems used for neurosurgery, providing a more precise, minimally invasive method for accessing targets in the brain.
- Biologics and Drug Development: Partnerships with pharmaceutical and biotech companies looking to deliver therapies across the blood-brain barrier for various neurological disorders.
Leadership and Structure
Joe Burnett is the President and CEO. The company has a standard corporate structure with functional departments such as R&D, Sales and Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- ClearPoint System: A neuro-navigation system for delivering drugs and gene therapies to the brain. The competitors are Medtronic, Monteris Medical. Clearpoint's market share information is not publicly available.
- SmartFrame: A key component of the ClearPoint System that enables real-time MRI guidance during procedures. The competitors are Medtronic, Monteris Medical. Clearpoint's market share information is not publicly available.
Market Dynamics
Industry Overview
The industry involves developing and providing minimally invasive neurosurgical technologies. There is a growing demand for targeted drug delivery and gene therapy techniques in treating neurological disorders.
Positioning
ClearPoint Neuro is positioned as a leader in MRI-guided neurosurgical solutions. Its competitive advantage lies in its real-time MRI guidance and its focus on delivering therapies across the blood-brain barrier.
Total Addressable Market (TAM)
The total addressable market for targeted drug delivery to the brain is estimated to be in the billions of dollars. ClearPoint is well-positioned to capture a significant portion of this TAM through its established platform and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary neuro-navigation technology
- Strong partnerships with pharmaceutical and biotech companies
- First-mover advantage in MRI-guided drug delivery
- Minimally invasive procedures
- Experienced leadership team
Weaknesses
- Limited revenue compared to larger medical device companies
- Dependence on partnerships for drug development
- Requires specialized MRI equipment for use
- High cost of initial setup
Opportunities
- Expansion of gene therapy applications
- Increased adoption of minimally invasive neurosurgery
- Further partnerships with pharmaceutical companies
- Development of new delivery methods and devices
- Geographic expansion into new markets
Threats
- Competition from larger medical device companies (Medtronic, Monteris)
- Regulatory hurdles for new drug delivery technologies
- Reimbursement challenges from healthcare providers
- Potential for technological obsolescence
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- MRIC
Competitive Landscape
ClearPoint Neuro's competitive advantage lies in its focus on MRI-guided drug delivery and its strong partnerships with pharmaceutical companies. However, it faces competition from larger medical device companies with greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: ClearPoint Neuro has experienced revenue growth in recent years, driven by increased adoption of its technology and expansion of its partnerships.
Future Projections: Analysts project continued revenue growth for ClearPoint Neuro, driven by the expanding market for gene therapies and the company's strategic partnerships.
Recent Initiatives: Recent strategic initiatives include expanding partnerships with pharmaceutical companies, investing in R&D to develop new delivery methods, and expanding commercial operations.
Summary
ClearPoint Neuro is a growing company positioned well in the neuro-navigation and targeted drug delivery market, driven by innovation and strategic partnerships. While facing competition and lacking profitability, the company is investing in research and development and expanding its commercial reach to benefit from a growing sector. The company must continue to enhance innovation and strengthen market position to achieve sustained success. Keep an eye on R&D costs and revenue increases.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data are estimates based on available information and may not be precise. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearpoint Neuro Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2020-02-12 | President, CEO & Director Mr. Joseph Michael Burnett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 115 | Website https://www.clearpointneuro.com |
Full time employees 115 | Website https://www.clearpointneuro.com | ||
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.